Product image of Midza (Lacosamide) supplied by GNH India

Midza

Active Ingredient:
Lacosamide
Origin:
EU

Midza (Lacosamide)

Lacosamide, the active ingredient in Midza, is a Sodium channel blocker presented as a tablet for oral use. It is used to treat partial‑onset seizures as part of epilepsy management in adults and children when appropriate.

GNH India supplies Midza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Belupo D.D.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lacosamide acts on neuronal sodium channels to control seizure activity in epilepsy.

  • Partial‑onset seizures: adjunctive treatment to reduce seizure frequency.
  • Epilepsy (adjunctive therapy): helps control seizures when other medications are insufficient.
  • Focal seizures (monotherapy): can be prescribed as initial therapy for seizure control.

How It Works

  • Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, stabilizing hyperexcitable neuronal membranes and decreasing repetitive neuronal firing. This modulation reduces the propagation of epileptiform activity without affecting normal neuronal function, contributing to seizure control in patients with focal epilepsy.

Side Effects

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Dizziness: transient sensation of light‑headedness.
  • Nausea: mild to moderate stomach upset.
  • Headache: occasional tension‑type headache.
  • Fatigue: feeling unusually tired or weak.
  • Blurred vision: temporary visual disturbances.
  • Diplopia: double vision in some patients.

Serious or Rare Side Effects

  • Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Suicidal ideation: emergence of depressive thoughts.
  • Hypersensitivity: rash, angioedema, or anaphylaxis.
  • Liver enzyme elevation: abnormal hepatic function tests.
  • Respiratory depression: especially when combined with other CNS depressants.

Precautions & Warnings

Before prescribing or dispensing lacosamide, consider the following safety measures.

  • Renal impairment: assess kidney function and adjust dose if necessary.
  • Hepatic impairment: monitor liver enzymes and consider dose modification.
  • Cardiac conduction disorders: avoid use in patients with known PR‑interval prolongation without cardiology input.
  • Pregnancy: risk category unknown; discuss potential benefits and risks with the prescriber.
  • Concomitant CNS depressants: monitor for additive sedation or respiratory effects.
  • Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Lacosamide can interact with several medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce lacosamide exposure.
  • Class I antiarrhythmics (e.g., quinidine): additive effects on cardiac conduction.
  • Carbamazepine: may lower lacosamide efficacy.

Moderate Interactions (Monitor Closely)

  • Other antiepileptic drugs: monitor seizure control and plasma concentrations.
  • Alcohol: may enhance central nervous system depression.
  • Tramadol: increased risk of seizures when combined.

Frequently Asked Questions

Midza contains the active ingredient lacosamide and is prescribed as an adjunctive therapy for partial‑onset (focal) seizures in patients with epilepsy. It may also be used as monotherapy for focal seizures when deemed appropriate by the treating physician.

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons, stabilizing hyper‑excitable membranes and reducing repetitive firing. This action limits the spread of epileptiform activity without affecting normal neuronal signaling, thereby helping to control seizures.

The dose of lacosamide is individualized. The prescribing clinician determines the appropriate starting dose, titration schedule, and maintenance dose based on the patient’s age, renal function, and response to therapy. Patients should follow the prescriber’s instructions precisely.

The pregnancy safety category for lacosamide is unknown. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Lactating mothers should discuss breastfeeding with their healthcare provider, as the drug may be excreted in breast milk.

To request Midza, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Midza (lacosamide) is a sodium‑channel blocker, differing from drugs such as carbamazepine or valproate that have broader mechanisms. Lacosamide’s selective enhancement of slow inactivation may result in a distinct side‑effect profile, often with fewer cognitive effects, but individual response varies.

Midza tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Midza is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water. The exact schedule (once or twice daily) depends on the individualized dosing plan.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and the emergence of suicidal thoughts. Patients should report any new cardiac symptoms, rash, or mood changes to their healthcare provider promptly.

Midza is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking interacting medications that could raise lacosamide levels.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lacosamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT